Achilles Therapeutics (ACHL) Competitors $1.02 +0.02 (+2.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACHL vs. NLTX, ELDN, LFVN, ADVM, SGMT, BDTX, TNYA, SCPH, GALT, and GBIOShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Neoleukin Therapeutics (NLTX), Eledon Pharmaceuticals (ELDN), LifeVantage (LFVN), Adverum Biotechnologies (ADVM), Sagimet Biosciences (SGMT), Black Diamond Therapeutics (BDTX), Tenaya Therapeutics (TNYA), scPharmaceuticals (SCPH), Galectin Therapeutics (GALT), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Neoleukin Therapeutics Eledon Pharmaceuticals LifeVantage Adverum Biotechnologies Sagimet Biosciences Black Diamond Therapeutics Tenaya Therapeutics scPharmaceuticals Galectin Therapeutics Generation Bio Neoleukin Therapeutics (NASDAQ:NLTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk. Do analysts rate NLTX or ACHL? Achilles Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 292.16%. Given Achilles Therapeutics' higher probable upside, analysts plainly believe Achilles Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAchilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer NLTX or ACHL? In the previous week, Achilles Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Achilles Therapeutics and 0 mentions for Neoleukin Therapeutics. Achilles Therapeutics' average media sentiment score of 0.98 beat Neoleukin Therapeutics' score of 0.00 indicating that Achilles Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Achilles Therapeutics Positive Does the MarketBeat Community favor NLTX or ACHL? Neoleukin Therapeutics received 33 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. However, 54.84% of users gave Achilles Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Achilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Is NLTX or ACHL more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Achilles Therapeutics N/A -47.24%-41.69% Which has more risk and volatility, NLTX or ACHL? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Which has preferable valuation and earnings, NLTX or ACHL? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-14.81Achilles TherapeuticsN/AN/A-$69.67M-$1.59-0.64 Do institutionals and insiders hold more shares of NLTX or ACHL? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryAchilles Therapeutics beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.91M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.6412.18115.5615.18Price / SalesN/A332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book0.294.024.665.02Net Income-$69.67M-$42.25M$119.06M$225.46M7 Day Performance4.08%8.06%0.80%0.37%1 Month Performance3.00%8.71%5.65%3.57%1 Year Performance20.00%32.10%36.76%29.44% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles Therapeutics2.8564 of 5 stars$1.02+2.0%$4.00+292.2%+21.4%$41.91MN/A-0.64250Positive NewsNLTXNeoleukin TherapeuticsN/A$43.74-3.1%N/A+240.8%$32.80MN/A-14.0690ELDNEledon Pharmaceuticals3.1811 of 5 stars$4.19+16.7%$16.00+281.9%+292.6%$166.16MN/A-2.0510Gap UpHigh Trading VolumeLFVNLifeVantage3.2054 of 5 stars$12.93-0.4%N/A+72.0%$164.22M$200.16M56.22260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageHigh Trading VolumeADVMAdverum Biotechnologies3.8273 of 5 stars$7.88+1.5%$28.17+257.4%-18.8%$163.57M$3.60M-0.99190Short Interest ↑SGMTSagimet Biosciences2.4607 of 5 stars$5.34-8.4%$24.00+349.4%+50.1%$162.30M$2M0.008Analyst ForecastNews CoverageBDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.87+0.3%$15.50+440.1%+56.6%$162.17MN/A-1.9190Upcoming EarningsShort Interest ↑TNYATenaya Therapeutics3.1245 of 5 stars$2.05+4.6%$15.25+643.9%+4.9%$161.72MN/A-1.34110Gap UpSCPHscPharmaceuticals3.4977 of 5 stars$4.46+0.7%$18.00+303.6%-22.2%$160.80M$24.05M-2.8630GALTGalectin Therapeutics1.6885 of 5 stars$2.52-0.8%$11.00+336.5%+24.4%$156.95MN/A-3.199Positive NewsGBIOGeneration Bio3.5469 of 5 stars$2.35-1.7%$7.50+219.1%+126.6%$156.84M$13.17M-0.98150Short Interest ↓ Related Companies and Tools Related Companies NLTX Alternatives ELDN Alternatives LFVN Alternatives ADVM Alternatives SGMT Alternatives BDTX Alternatives TNYA Alternatives SCPH Alternatives GALT Alternatives GBIO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
